Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that it has signed a strategic collaboration agreement with DP Technology, a scientific intelligence company, to jointly advance the design and optimization of payload molecules for antibody-drug conjugates (ADCs). The partnership will integrate Anke Biotechnology’s biopharmaceutical R&D strengths with DP Technology’s AI for Science capabilities, aiming to improve the efficiency of candidate molecule design and optimization and to support the development of the company’s innovative drug pipelines.
Partnership Milestone
| Item | Detail |
|---|---|
| Parties | Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) and DP Technology |
| Agreement Type | Strategic collaboration agreement |
| Focus Area | AI-driven design and optimization of payload molecules for antibody-drug conjugates (ADCs) |
| Signing Date | 16 Sep 2026 |
| Financial Terms | Not disclosed |
| Strategic Objective | Promote AI for Science in innovative drug R&D; enhance candidate molecule design and optimization efficiency; support innovative pipeline development |
Collaboration Scope & Technology Stack
- AI Capabilities (DP Technology): Molecular simulation, free energy calculation, quantitative structure-activity relationship (QSAR) analysis, and ADMET prediction (absorption, distribution, metabolism, excretion, and toxicity).
- Design Tasks: Structural generation and virtual screening of payload candidate molecules, aligned with Anke Biotechnology’s actual R&D requirements.
- Property Prediction: Forecasting of key physicochemical properties of payload candidates prior to synthesis.
- Resistance Assessment: Evaluation of efflux transporter-related resistance risks, an early-stage consideration for durable payload activity.
- Optimization Criteria: Comprehensive balancing of molecular activity, selectivity, safety, and synthetic feasibility.
- Closed-Loop Workflow: A “computational design — experimental validation — data feedback” cycle, combining experimental data with mechanistic analysis to continuously refine prediction models and molecular design, thereby enhancing the efficiency of candidate molecule discovery and optimization.
ADC Payload Design – Scientific Rationale
- Why Payloads Matter: In an ADC, the cytotoxic payload determines much of the drug’s potency and therapeutic window; small structural changes can materially affect activity, stability, and safety profiles.
- The Design Bottleneck: Conventional payload optimization relies on iterative synthesis and testing, which is time-consuming and resource-intensive; in silico generation and screening can prioritize the most promising candidates before lab work begins.
- Physics-Based Precision: Free energy calculation enables quantitative estimation of binding and property changes, while ADMET modeling flags safety and developability liabilities earlier in discovery.
- Resistance Foresight: Efflux transporter-mediated drug efflux is a recognized resistance mechanism; assessing this risk computationally supports the selection of payloads with more durable activity.
Market Impact & Outlook
- China ADC Landscape: Chinese biopharma companies have become deeply engaged in ADC development, and payload-linker innovation remains a central axis of differentiation in this competitive modality.
- AI for Science Momentum: The agreement reflects the broader trend of pharmaceutical R&D adopting scientific-intelligence platforms to compress discovery timelines and reduce attrition in early-stage candidate optimization.
- Anke Biotechnology’s Pipeline Strategy: For the ChiNext-listed biopharmaceutical group, embedding AI into payload design supports the construction of next-generation innovative pipelines alongside its established biologics portfolio.
- Efficiency Gains: Through the closed-loop computational-experimental workflow, the partners aim to accelerate candidate molecule discovery and continuously improve model accuracy with proprietary experimental data.
- Next Steps: Joint execution of the closed-loop R&D program; specific pipeline candidates, milestones, and timelines were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration between Anke Biotechnology and DP Technology, including expectations for AI-assisted payload molecule design, pipeline development, and R&D efficiency. Actual results may differ due to risks including model performance, experimental validation outcomes, regulatory requirements, and competitive dynamics. No financial terms of the agreement have been disclosed.-Fineline Info & Tech
